Built with Ventus Therapeutics, Inflammasome Therapeutics, Merck & more, the Inflammasome Therapeutics Summit returns for its third year as the only industry-dedicated forum to discover the intricacies of inflammasome regulation and accelerate novel inflammasome therapeutics into proof-of-concept clinical trials and beyond! With a plethora of inflammasome-targeted drugs poised to enter the clinic in 2021, this year’s summit will once again unite thought leaders in inflammasome drug development. Expect to be involved in interactive discussions on:- How dysregulated inflammasome activation, formation and signalling contribute to disease and how to identify novel drug targets beyond NLRP3- The interface of inflammasome signalling with innate immunity, microbial interactions, metabolism, neuroimmune and other systems- Leveraging inflammasome proteins in precision-based medicine as disease biomarkers and companion diagnostics in both the preclinical and clinical setting- Identifying and translating the most promising therapeutic applications of inflammasome-targeted drugs across monogenic diseases, as well as infectious, ophthalmic, neurological and cancer settings this year’s meeting has two parallel tracks of learning with 30+ speakers sharing highly anticipated case studies. As the growth potential of novel inflammasome therapeutics becomes apparent, join the conversation to validate novel inflammasome targets beyond NLRP3 and realize the clinical and commercial potential of inflammasome proteins across different diseases!